J
Jean-Pierre Bronowicki
Researcher at University of Lorraine
Publications - 278
Citations - 18104
Jean-Pierre Bronowicki is an academic researcher from University of Lorraine. The author has contributed to research in topics: Ribavirin & Hepatocellular carcinoma. The author has an hindex of 59, co-authored 259 publications receiving 15534 citations. Previous affiliations of Jean-Pierre Bronowicki include Nancy-Université & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix,Shukui Qin,Philippe Merle,Alessandro Granito,Yi Hsiang Huang,György Bodoky,Marc Pracht,Osamu Yokosuka,Olivier Rosmorduc,Valeriy Breder,René Gerolami,Gianluca Masi,Paul Ross,Tianqiang Song,Jean-Pierre Bronowicki,Isabelle Ollivier-Hourmand,Masatoshi Kudo,Ann-Lii Cheng,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Richard S. Finn,Marie Aude Leberre,Annette Baumhauer,Gerold Meinhardt,Guohong Han +25 more
TL;DR: Regorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenIB treatment, and future trials should explore combinations of regorAFenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafanib and regorafinib.
Journal ArticleDOI
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Christophe Hézode,Nicole Forestier,Geoffrey Dusheiko,Peter Ferenci,Stanislas Pol,Tobias Goeser,Jean-Pierre Bronowicki,Marc Bourlière,Shahin Gharakhanian,Leif Bengtsson,Lindsay McNair,Shelley George,Tara L. Kieffer,Ann D. Kwong,Robert S. Kauffman,John Alam,Jean-Michel Pawlotsky,Stefan Zeuzem +17 more
TL;DR: In this phase 2 study of patients infected with HCV genotype 1 who had not been treated previously, one of the three telaprevir groups had a significantly higher rate of sustained virologic response than that with standard therapy.
Journal ArticleDOI
Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus Infection
Olivier Hermine,François Lefrère,Jean-Pierre Bronowicki,Xavier Mariette,Katayoun Jondeau,Virginie Eclache-Saudreau,Béatrice Delmas,Françoise Valensi,Patrice Cacoub,Christian Bréchot,Bruno Varet,Xavier Troussard +11 more
TL;DR: In patients with splenic lymphoma with villous lymphocytes who are infected with HCV, treatment with interferon can lead to regression of the lymphoma.
Journal ArticleDOI
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
Valérie Vilgrain,Valérie Vilgrain,Helena Pereira,Eric Assenat,Boris Guiu,Alina Diana Ilonca,Georges-Philippe Pageaux,Annie Sibert,Mohamed Bouattour,Rachida Lebtahi,Wassim Allaham,Hélène Barraud,Valérie Laurent,Elodie Mathias,Jean-Pierre Bronowicki,Jean-Pierre Tasu,Rémy Perdrisot,Christine Silvain,René Gerolami,Olivier Mundler,Jean-François Seitz,Vincent Vidal,Christophe Aubé,Frédéric Oberti,Olivier Couturier,Isabelle Brenot-Rossi,Jean-Luc Raoul,Anthony Sarran,Charlotte Costentin,Emmanuel Itti,Alain Luciani,Alain Luciani,René Adam,Maïté Lewin,Didier Samuel,Maxime Ronot,Maxime Ronot,Aurelia Dinut,Laurent Castera,Laurent Castera,Gilles Chatellier,Gilles Chatellier,Elisabeth Delhom Christol,Alina D. Ilonca,Julie Lonjon,Mohamed Abdel-Rehim,Arnaud Dieudonné,Christophe Bazin,Carine Chagneau-Derrode,Patrick Borentain,Antoine Bouvier,Laurent Vervueren,Julia Chalaye,Hicham Kobeiter,Julien Edeline,Etienne Garin,Yan Rolland,Isabelle Archambeaud,T. Eugène,Eric Frampas,Christophe Cassinotto,Martine Guyot,Jean-Baptiste Hiriart,Bruno Lapuyade,Julien Vergniol,Philippe Bachellier,Julien Detour,Bernard Duclos,Michel Greget,Francois Habersetzer,Alessio Imperiale,Philippe Merle,Agnès Rode,Julie Morvan,Eric Nguyen-Khac,Thierry Yzet,G. Baudin,Patrick Chevallier,Abakar Mahamat,Thierry Piche,Micheline Razzouk,Patrick Hillon,Romaric Loffroy,Michel Toubeau,Julie Vincent,Gabriele Barabino,Nadia Bouarioua,Muriel Cuilleron,Marie Ecochard,Nathalie Prevot-Bitot,Vincent Leroy,J. Roux,Christian Sengel,Valérie Bourcier,Nathalie Ganne-Carrié,Olivier Seror,Sylvie Costo,Thong Dao,Jean-Pierre Pelage,Jérôme Dumortier,Francesco Giammarile,Pierre-Jean Valette,Nadia Ghazzar,Olivier Pellerin,Julien Taieb,Pierre Weinmann,Alexandra Heurgue-Berlot,Claude Marcus,Daniele Sommacale,Maria-Angéla Castilla-Lièvre,Sophie Maitre,Lysiane Marthey +111 more
TL;DR: SarAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy in patients with hepatocellular carcinoma.
Journal ArticleDOI
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
Christophe Hézode,Hélène Fontaine,Céline Dorival,Dominique Larrey,Fabien Zoulim,Valérie Canva,Victor de Lédinghen,Thierry Poynard,Didier Samuel,Marc Bourlière,Jean-Pierre Zarski,J.-J. Raabe,Laurent Alric,Patrick Marcellin,Ghassan Riachi,Pierre-Henri Bernard,Véronique Loustaud-Ratti,Sophie Metivier,Albert Tran,Lawrence Serfaty,Armand Abergel,Xavier Causse,Vincent Di Martino,Dominique Guyader,Damien Lucidarme,Véronique Grando-Lemaire,Patrick Hillon,Cyrille Feray,Thong Dao,Patrice Cacoub,Isabelle Rosa,Pierre Attali,Ventzislava Petrov-Sanchez,Yoann Barthe,Jean-Michel Pawlotsky,Stanislas Pol,Fabrice Carrat,Jean-Pierre Bronowicki +37 more
TL;DR: The safety profile was poor and patients with platelet count ≤ 100,000/mm(3) and serum albumin <35 g/L should not be treated with the triple therapy, and the on-treatment virological response was high.